Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ironwood Pharmaceuti
(NQ:
IRWD
)
6.480
-0.160 (-2.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ironwood Pharmaceuti
< Previous
1
2
3
4
5
Next >
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
May 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
May 08, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Recap: Ironwood Pharmaceuticals Q1 Earnings
May 04, 2023
Via
Benzinga
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
May 04, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For February 16, 2023
February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...
Via
Benzinga
Earnings Outlook For Ironwood Pharmaceuticals
February 15, 2023
Via
Benzinga
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
April 24, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
April 20, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
February 27, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
February 16, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
February 13, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
3 No-Brainer Stocks to Buy Right Now for Less Than $25
February 04, 2023
All three healthcare stocks are showing solid long-term potential.
Via
The Motley Fool
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
February 02, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Why Ironwood Pharmaceuticals Shares Are Falling During Monday's Session
January 09, 2023
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares are trading lower by 10.00% to $11.30 Monday afternoon after the company cut its FY22 sales guidance below analyst estimates and issued FY23 sales...
Via
Benzinga
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
January 09, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
November 03, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
October 20, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Shares Positive Top-line Data From Late-Stage Functional Constipation Candidate Study In Patients Aged 6-17 Years
September 06, 2022
Ironwood Pharmaceuticals (NASDAQ: IRWD) announced positive top-line data from its Phase 3 clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional...
Via
Benzinga
Ironwood's Constipation Drug Shows Efficacy In Pediatric Patients
September 06, 2022
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) announced topline data from a Phase 3 trial evaluating Linzess (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation.
Via
Benzinga
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
September 06, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
September 01, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Wells Fargo Maintains Equal-Weight Rating for Ironwood Pharmaceuticals: Here's What You Need To Know
August 16, 2022
Wells Fargo has decided to maintain its Equal-Weight rating of Ironwood Pharmaceuticals (NASDAQ:IRWD) and raise its price target from $12.00 to $13.00. Shares of Ironwood Pharmaceuticals are trading...
Via
Benzinga
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
August 04, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
July 21, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
5 Value Stocks In The Healthcare Sector
July 18, 2022
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
The Daily Biotech Pulse: Third FDA Rejection For Verrica's Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva's Chikungunya Vaccine
May 25, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
May 25, 2022
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.